Status:

RECRUITING

A Study of TIL in Advanced Solid Tumors (DFGD)

Lead Sponsor:

Shanghai Juncell Therapeutics

Collaborating Sponsors:

Eastern Hepatobiliary Surgery Hospital

Conditions:

Advanced Solid Tumor

Tumor Infiltrating Lymphocytes

Eligibility:

All Genders

18-75 years

Phase:

EARLY_PHASE1

Brief Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor...

Eligibility Criteria

Inclusion

  • have one the tumor resection for TILs production and successfully produced;
  • Age: 18 years to 75years;
  • Histologically diagnosed as solid tumors;
  • Expected life-span more than 3 months;
  • ECOG score 0-1;
  • Test subjects have failed standard treatment regimens, and be willing to receive TIL therapy;
  • At least 1 evaluable tumor lesion;

Exclusion

  • with other malignant tumors, except for the malignancies that have been cured, have been inactive for ≥5 years prior to study inclusion and have a very low risk of recurrence; Non-melanoma skin cancer or malignant lentigo with adequate treatment and no evidence of disease recurrence; Carcinoma in situ with adequate treatment and no evidence of disease recurrence;
  • Need glucocorticoid treatment, and daily dose of Prednisone greater than 10mg(or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;
  • Breathe indoor air in a quiet state, and the oxygen saturation of finger pulse is \< 95%;
  • Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;
  • Significant cardiovascular anomalies

Key Trial Info

Start Date :

April 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2027

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06488950

Start Date

April 1 2023

End Date

June 30 2027

Last Update

December 16 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Third Affiliated Hospital of Naval Medical University

Shanghai, China